Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2019 · 10-Q
Revenue$874.95K$874.95K+86.5% vs Q3 2018 Net Income-$2.63M-$2.63MN/M vs Q3 2018 EPS Diluted-$0.73-$0.73N/M vs Q3 2018 Operating Income-$3,760,165N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-429.8%−362.9 pt vs Q3 2018
Net margin-300.3%−234.8 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end